ClinicalTrials.gg
Not yet recruitingNCT07684690AI-ADCSUpdated Jul 6, 2026

AI-Assisted Antidiabetic Drug Consultation System for Glycemic Control in Type 2 Diabetes Patients Managed by Non-Specialist Physicians

An interventional study of AI-assisted antidiabetic drug consultation system and Manual antidiabetic prescribing (without AI) in Type 2 Diabetes Mellitus (T2DM), sponsored by National Taiwan University Hospital. Not yet recruiting at 1 site in Taiwan. Open to participants aged 19 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by National Taiwan University Hospital · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
19 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Diabetes Mellitus, Type 2 by National Taiwan University Hospital — 9 open to participants now, 9 under way, none of them phase 3. Diabetes Mellitus, Type 2 · National Taiwan University Hospital.

Started
2026
with 2 others
No phase
8 of 17
5 open now
Registered
16th of 17
by date

Among the 17 studies in Diabetes Mellitus, Type 2 by National Taiwan University Hospital, this one is one of 3 that started in 2026, is one of 8 with no phase, and was the 16th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

9 of the 17 studies in Diabetes Mellitus, Type 2 by National Taiwan University Hospital are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 19 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Diabetes Mellitus, Type 2 by National Taiwan University Hospital, or all of them as a file.
02

Study summary

This study tests whether an artificial intelligence (AI) tool can help doctors choose better diabetes medicines for their patients. Type 2 diabetes is very common, but there are far more patients than diabetes specialists, so many patients are treated by doctors who are not diabetes specialists. The researchers built an AI consultation system that gives doctors real-time suggestions and predictions about diabetes medicines while they are prescribing. The doctor always makes the final decision.

In this trial, patients with type 2 diabetes whose blood sugar is not well controlled will be placed by chance (randomly) into one of two groups. In one group, the doctor uses the AI system when deciding on diabetes medicines. In the other group, the doctor prescribes as usual, without the AI system. All medicines used are already approved in Taiwan and given at approved doses.

The study follows each patient for 12 months, with check-ups at the start and at 3, 6, 9, and 12 months. The main goal is to compare how much the patients' long-term blood sugar level (HbA1c) improves between the two groups after one year. The researchers also look at how many patients reach their blood sugar target, how often low blood sugar happens, and whether any side effects occur. The aim is to find out whether using the AI tool leads to better blood sugar control.

03

Conditions studied

  • Type 2 Diabetes Mellitus (T2DM)
04

Who can participate

Ages eligible
19 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 to 80 years
  • Diagnosis of type 2 diabetes for at least 6 months
  • above 8% within the past 3 months
  • Currently using one or more oral antidiabetic drugs
  • Able to understand and provide written

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or breastfeeding
  • Recent participation in another interventional clinical trial
  • Cognitive impairment precluding understanding of the study
  • Active cancer treatment within the past 6 years
  • Use of systemic
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    AI-Assisted Prescribing

    Non-specialist physicians prescribe antidiabetic medications after consulting the AI-assisted antidiabetic drug consultation system. The system provides real-time, interactive prescribing recommendations, a drug-prioritization order, and outcome predictions. The physician retains full control over the final prescribing decision. All medications are approved in Taiwan and prescribed within approved dose ranges. Patients are followed for 12 months.

    Device: AI-assisted antidiabetic drug consultation system

  • Active comparator
    Manual Prescribing (Non-AI)

    Non-specialist physicians prescribe antidiabetic medications manually according to usual clinical practice, without using the AI consultation system. All medications are approved in Taiwan and prescribed within approved dose ranges. Patients are followed for 12 months.

    Other: Manual antidiabetic prescribing (without AI)

Interventions

  • DeviceAI-assisted antidiabetic drug consultation system

    A machine-learning based clinical decision support software that provides non-specialist physicians with real-time, interactive antidiabetic prescribing recommendations, a drug-prioritization order, and outcome predictions (e.g., the predicted likelihood of reaching glycemic targets and responder/non-responder status for individual drugs). The system was developed and validated using the NTUH integrated medical database platform. It provides advisory recommendations only; the treating physician retains full control over the final prescribing decision. All recommended medications are approved in Taiwan and within approved dose ranges.

  • OtherManual antidiabetic prescribing (without AI)

    Antidiabetic medications prescribed manually by non-specialist physicians according to usual clinical practice, without using the AI consultation system. All medications are approved in Taiwan and prescribed within approved dose ranges.

06

What researchers measure

Primary outcomes

  1. Change in HbA1c from baseline to 12 months

    The between-group difference in the change in glycated hemoglobin (HbA1c) from baseline to 12 months, comparing the AI-assisted prescribing arm with the manual prescribing (control) arm. HbA1c reflects long-term glycemic control. The primary analysis uses analysis of covariance (ANCOVA) adjusting for baseline HbA1c, following the intention-to-treat principle.

    Time frame: Baseline and 12 months

Secondary outcomes

  1. Proportion of participants achieving HbA1c < 7.0% at 12 months

    The proportion of participants reaching the glycemic target of HbA1c below 7.0% at 12 months, compared between arms using chi-square tests.

    Time frame: 12 months

  2. Incidence of hypoglycemia over 12 months

    Incidence of hypoglycemic events over the 12-month follow-up, graded by severity: Level 1, glucose \< 70 mg/dL (3.9 mmol/L) and ≥ 54 mg/dL (3.0 mmol/L); Level 2, glucose \< 54 mg/dL (3.0 mmol/L); Level 3, severe hypoglycemia requiring assistance of another person regardless of glucose value. Compared between arms using Poisson regression.

    Time frame: Up to 12 months

  3. Incidence of prespecified adverse events over 12 months

    Incidence of prespecified adverse events over the 12-month follow-up, including urinary tract infection, lower-limb edema, signs of heart failure, fractures, nausea, vomiting, and diarrhea. Compared between arms using Poisson regression.

    Time frame: Up to 12 months

  4. Change in HbA1c from baseline at 3, 6, 9, and 12 months

    Time frame: Baseline, 3, 6, 9, and 12 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Nov 2027, 16 months later.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 16 months is below that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2026
First posted
Jul 6, 2026
StartEst.
Jul 2026
Primary completionEst.
Nov 2027
CompletionEst.
Nov 2027
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07684690
Responsible party
Sponsor
First posted
Jul 6, 2026
Start date
Jul 2026 (estimated)
Primary completion
Nov 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Jul 6, 2026

Study contacts

Yi-Cheng Chang, M.D.
Contact
b83401040@gmail.com
886+0972651027
Pan Hou Che, PhD student
Contact
d12456001@g.ntu.edu.tw
886+0987197997

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion